Literature DB >> 25043151

Characterization of the enterovirus 71 VP1 protein as a vaccine candidate.

Shi-Li Zhou1, Xiao-Ling Ying, Xue Han, Xian-Xun Sun, Qi Jin, Fan Yang.   

Abstract

Enterovirus 71 (EV71) is an important agent responsible for hand-foot-and-mouth disease (HFMD), which can cause severe neurological complications and death in children. However, there is no specific treatment for EV71 infection, and a safe and effective vaccine is needed urgently. In this study, an effective and economical method for the production of EV71-VP1 protein was developed, and the VP1 protein was evaluated in humoral and cellular immune responses as an EV71 vaccine. The results revealed that the VP1 protein induced high titers of cross-neutralizing antibodies for different EV71 subtypes, and elicited significant splenocyte proliferation. The high levels of IFN-r and IL-10 showed the VP1 protein induced a mixed Th1 and Th2 immune response. Vaccinated female mice could confer protection in their neonatal offspring. Compared with the inactivated EV71, the VP1 protein elicited similar humoral and cellular responses, but the engineered protein is safer, less expensive and can be produced more efficiently. Therefore, EV71-VP1 protein can induce effective immunologic protection against EV71 and is an ideal candidate against EV71 infection.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  EV71; HFMD; VP1 protein; immunogenicity; vaccine

Mesh:

Substances:

Year:  2014        PMID: 25043151     DOI: 10.1002/jmv.24018

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  8 in total

1.  Monoclonal neutralizing antibodies against EV71 screened from mice immunized with yeast-produced virus-like particles.

Authors:  Tao Lin; Lingzhi Xianyu; Songya Lyu
Journal:  Virol Sin       Date:  2015-05-29       Impact factor: 4.327

2.  GITRL as a genetic adjuvant enhances enterovirus 71 VP1 DNA vaccine immunogenicity.

Authors:  Jing Yuan; Xinyi Tang; Kai Yin; Jie Tian; Ke Rui; Jie Ma; Chaoming Mao; Jianguo Chen; Liwei Lu; Huaxi Xu; Shengjun Wang
Journal:  Immunol Res       Date:  2015-05       Impact factor: 2.829

3.  Development of an Enterovirus 71 Vaccine Efficacy Test Using Human Scavenger Receptor B2 Transgenic Mice.

Authors:  Ayumi Imura; Yui Sudaka; Ayako Takashino; Kanami Tamura; Kyousuke Kobayashi; Noriyo Nagata; Hidekazu Nishimura; Katsumi Mizuta; Satoshi Koike
Journal:  J Virol       Date:  2020-02-28       Impact factor: 5.103

Review 4.  Antivirals and vaccines for Enterovirus A71.

Authors:  Jing-Yi Lin; Yu-An Kung; Shin-Ru Shih
Journal:  J Biomed Sci       Date:  2019-09-03       Impact factor: 8.410

Review 5.  Enterovirus A71 Vaccines.

Authors:  Mei-Ling Li; Shin-Ru Shih; Blanton S Tolbert; Gary Brewer
Journal:  Vaccines (Basel)       Date:  2021-02-27

6.  Quantitative Proteomic Analysis of Escherichia coli Heat-Labile Toxin B Subunit (LTB) with Enterovirus 71 (EV71) Subunit VP1.

Authors:  Lin Liu; Yongping Ma; Huicong Zhou; Mingjun Wu
Journal:  Int J Mol Sci       Date:  2016-08-27       Impact factor: 5.923

7.  Virological investigation of genetic variation of enterovirus type 71 in hand, foot and mouth disease.

Authors:  Yang Wang; Yi Li; Yuling Yang; Chuanmei Peng; Xiaoye Fu; Xin Gu; Hui Gao
Journal:  Exp Ther Med       Date:  2020-05-07       Impact factor: 2.447

Review 8.  Insights into innate and adaptive immune responses in vaccine development against EV-A71.

Authors:  Hui Xuan Lim; Chit Laa Poh
Journal:  Ther Adv Vaccines Immunother       Date:  2019-11-21
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.